Haematologica · 2009 · 65 citations · 23 references
Life SciencesMolecular BiologyMolecular GeneticsCancer GeneticsImmunogeneticsMolecular Cell BiologyLymphoid NeoplasmsLymphoid TissueLymphoid Tissue PathologyLymphoid TumorsGenetic Mutation FrequencyLymphoid Neoplasm PathogenesisLymphoma PathogenesisNf-kappa B-dependent TranscriptionNuclear Factor Kappa B Signaling
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) shows constitutive NF-kappaB activity in the malignant lymphocyte-predominant (LP) cells. Constitutive NF-kappaB activity also plays a central pathogenetic role in classical Hodgkin's lymphoma (cHL), where inactivating mutations in the NFKBIA and TNFAIP3 genes, coding for the negative NF-kappaB regulators IkappaBalpha and A20, respectively, contribute to NF-kappaB activation. To determine whether mutations in NFKBIA and TNFAIP3 are also involved in the pathogenesis of NLPHL these genes were sequenced from microdissected LP cells of 10 primary NLPHL. We also studied DEV, the only cell line proposedly derived from LP cells, after we had confirmed its derivation from NLPHL by gene expression analysis. A heterozygous somatic missense mutation in the NFKBIA gene was found in one NLPHL, and a heterozygous, possibly subclonal, two base pair insertion in TNFAIP3 in another case. The low mutation frequency and the absence of biallelic destructive mutations propose a minor contribution of NFKBIA and TNFAIP3 mutations to the NF-kappaB activity of NLPHL, suggesting different mechanisms of NF-kappaB activation in NLPHL and cHL.
23
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling
Ingrid E. Wertz, Karen O’Rourke, Honglin Zhou et al. · Nature · 2004 · 1.8K citations
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno, Wei Keat Lim, Adina Grunn et al. · Nature · 2009 · 1K citations
Frequent inactivation of A20 in B-cell lymphomas
Motohiro Kato, Masashi Sanada, Itaru Kato et al. · Nature · 2009 · 549 citations
Medicine, Hematology, Oncology +9